Down with Big Brother [NCA / SHAM]

posted by Helmut Homepage – Vienna, Austria, 2019-02-04 13:43 (803 d 10:20 ago) – Posting: # 19860
Views: 4,519

Hi Nastia,

» Through "atavism" I meant something like a tail in human body - smthg that should be dissapeared while evolution.

OK, but atavism works the other way ’round. A baby born with a tail. An anachronism would be using a sliding rule instead of pocket calculator.

» May I clarify once more: for non-comparative PK trials of IR do we need only classical global Cmin?

Not sure what you mean by “non-comparative PK trial of IR”. For IR you don’t need it at all (Cmin,ss was suggested in the draft IR-GL but didn’t make it to the final version). In the comments we find the nice apples-and-oranges sentence:

“By Cmin,ss we mean the concentration at the end of the dosage interval, i.e. Ctrough.”

Given. Common understanding: Cmin,ss = Ctrough, which is  Cτ,ss in case of a lag-time. Even without a lag-time due to variability Cmin,ss can be observed at the beginning or the end of the dosing interval. Sigh.

In a hybrid application (no MR on the market; comparison to IR or even a solution) I would say Css,min. BTW, currently I’m dealing with a hybrid for Canada. It’s a biphasic product with a lag-time. After some to-and-fro: Both Css,min and Cτ,ss. Oh dear…

» Аnd for MR Ctrough (as it is written in the article)?

Yep – if the two Lászlós meant Cτ,ss. ;-)

Dif-tor heh smusma 🖖
Helmut Schütz

The quality of responses received is directly proportional to the quality of the question asked. 🚮
Science Quotes

Complete thread:

 Admin contact
21,419 posts in 4,475 threads, 1,511 registered users;
online 16 (0 registered, 16 guests [including 2 identified bots]).
Forum time: Sunday 00:03 UTC (Europe/Vienna)

Nothing fails like success because you do not learn anything from it.
The only thing we ever learn from is failure.
Success only confirms our superstitions.    Kenneth E. Boulding

The Bioequivalence and Bioavailability Forum is hosted by
BEBAC Ing. Helmut Schütz